Delving into the Latest Updates on Zymenex A/S with Synapse

概览

关联

10

项与 Zymenex A/S 相关的临床试验

NCT02478840

/ Completed临床3期

A Single Center, Open Label Clinical Trial Investigating the Long-term Efficacy of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) Treatment in Subjects With Alpha-Mannosidosis Who Previously Participated in Lamazym Trials

The overall objective is to evaluate the long-term efficacy of Lamazym i.v. treatment in patients with alpha-Mannosidosis previously enrolled in Lamazym trials and currently receiving the treatment according to the AfterCare Program.

开始日期2015-02-01

申办/合作机构

Zymenex A/S

EUCTR2014-003950-15-DK

/ Not yet recruitingN/A

A single center, open label clinical trial investigating the long-term efficacy of rhLAMAN (recombinant human alpha-mannosidase or Lamazym) treatment in subjects with alpha-Mannosidosis who previously participated in Lamazym trials

开始日期2015-01-22

申办/合作机构

Zymenex A/S

NCT01681953

/ Completed临床3期

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis.

The overall objective of this trial is to evaluate the efficacy and safety of repeated Lamazym i.v. treatment, compared with placebo, in subjects 5-35 years of age with alpha-Mannosidosis

开始日期2012-08-01

申办/合作机构

Zymenex A/S

100 项与 Zymenex A/S 相关的临床结果

登录后查看更多信息

0 项与 Zymenex A/S 相关的专利（医药）

登录后查看更多信息

100 项与 Zymenex A/S 相关的药物交易

登录后查看更多信息

100 项与 Zymenex A/S 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年04月28日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

其他

7

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

ACE-393	腹泻更多	终止
ETEC vaccine(Acambis Plc)	腹泻更多	终止
G-0107 ( Enzymes )	遗传病更多	无进展
Cerebroside sulfatase ( ASA )	异染性脑白质病变更多	无进展
ACE-720	肺炎球菌感染更多	无进展